High Throughput Screening of Antibody Drug Based on 3Dmicroflu™

CD BioSciences is a growing life science company focusing on 3D bioprinting fields such as bio-ink design, 3D printing technology platform development and in vitro research micro-models customization. Here, our experienced experts can provide you with a series of 3d printing bioinks and solutions based on 3Dmicroflu™ technology platform for you to choose from according to your project needs. In the process of drug development, no matter what type of drug, models are needed for the initial drug screening. CD BioSciences can help you achieve high throughput in drug screening by replacing inaccurate 2D cell and animal models. Do you consider choosing 3Dmicroflu™ technology platform to advance your in vitro drug screening process? The following shows the application of 3Dmicroflu™ technology platform in advancing the antibody drug development process.

Overview of antibody drug R&D

Antibody drugs are prepared by antibody engineering technology mainly based on cell engineering and genetic engineering techniques. Antibodies have the advantages of high specificity, homogeneous nature, good safety, and can be prepared in a targeted manner for specific targets, which have wide application prospects in the treatment of various major diseases. With the advancement of research in the antibody field, the variety of emerging antibody drugs is also increasing.

High Throughput Screening of Antibody Drug Based on 3Dmicroflu™

  • Small molecule antibody drugs
  • Antibody-coupled drugs
  • Bispecific antibody drugs
  • GPCR antibody drugs

Based on the rapid development trend of antibody drugs, the requirement for screening models in the screening process of antibodies is also increasing. 3D bioprinting technology has been used to participate in the construction of antibody drug screening models. At CD BioSciences, higher resolution 3D bioprinting can be achieved through 3Dmicroflu™ technology platform that accelerates the development process of various antibody drugs.

3Dmicroflu™ for the construction of the high-throughput in vitro antibody drugs screening micro-models

Different from traditional drugs, antibody drugs have the advantage of better specificity and more functional flexibility. However, antibody drugs are more difficult to develop as large molecules, and immunogenicity in particular has always been a key concern in the development of therapeutic antibodies. Here, CD BioSciences' proprietary 3D printing 3Dmicroflu™ technology platform can provide you with disease models and immune system models that fully simulate the in vivo physiological environment to support your antibody screening efforts. The general flow of 3Dmicroflu™ technology platform involved in antibody drug screening is shown in the diagram below.

3Dmicroflu™ technology platform is involved in the construction of disease models and immune system models for the rapid screening process of antibody drugs - CD BioSciences.Fig. 1. 3Dmicroflu™ technology platform is involved in the construction of disease models and immune system models for the rapid screening process of antibody drugs.

Firstly, 3Dmicroflu™ technology platform can be involved in the construction of many types of disease models, such as various tumor models, autoimmune disease models, cardiovascular disease models, etc. Our high-resolution technology platform is well suited for the printing of complex models, and if you choose 3Dmicroflu™ you do not have to worry about the complex screening structures involved in your antibody development project. In addition, once you get in touch with us, we will arrange a team of professional and experienced experts to provide you with a full consultation service for your order.

Secondly, immunogenicity is the property that elicits an immune response. Validation of immunogenicity has always been one of the important criteria for antibody screening and an important step to ensure the safety of antibody drugs. 3Dmicroflu™ technology platform can provide in vitro immune system micro-models for your immunogenicity validation process, which can fully reflect the real physiological environment characteristics in vivo and simulate the immunogenicity effect of antibody drugs in vivo.

If you have a need for the 3Dmicroflu™ technology platform for high-throughput screening of antibody drugs in your drug development program, please feel free to contact us for customization of the immune organ and system. We always hope that 3Dmicroflu™ technology platform will provide great assistance and guidance to your drug development process.

For research use only, not intended for any clinical use.